Morgan Stanley’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.4M | Sell |
167,229
-26,173
| -14% | -$5.18M | ﹤0.01% | 2495 |
|
|
2025
Q4 | $36.6M | Buy |
193,402
+4,701
| +2% | +$903K | ﹤0.01% | 2386 |
|
|
2025
Q3 | $33.4M | Sell |
188,701
-13,708
| -7% | -$2.04M | ﹤0.01% | 2387 |
|
|
2025
Q2 | $23M | Sell |
202,409
-36,683
| -15% | -$3.92M | ﹤0.01% | 2662 |
|
|
2025
Q1 | $25.1M | Buy |
239,092
+31,230
| +15% | +$3.53M | ﹤0.01% | 2459 |
|
|
2024
Q4 | $22.3M | Sell |
207,862
-29,151
| -12% | -$3.3M | ﹤0.01% | 2644 |
|
|
2024
Q3 | $23.7M | Buy |
237,013
+42,675
| +22% | +$4.3M | ﹤0.01% | 2632 |
|
|
2024
Q2 | $16.4M | Sell |
194,338
-57,559
| -23% | -$4.58M | ﹤0.01% | 2879 |
|
|
2024
Q1 | $18.4M | Sell |
251,897
-146,491
| -37% | -$10.8M | ﹤0.01% | 2786 |
|
|
2023
Q4 | $28.5M | Buy |
398,388
+203,381
| +104% | +$12M | ﹤0.01% | 3020 |
|
|
2023
Q3 | $11.7M | Buy |
195,007
+26,741
| +16% | +$1.76M | ﹤0.01% | 2981 |
|
|
2023
Q2 | $12.1M | Buy |
168,266
+13,187
| +9% | +$989K | ﹤0.01% | 2983 |
|
|
2023
Q1 | $11.4M | Sell |
155,079
-29,491
| -16% | -$2.1M | ﹤0.01% | 3028 |
|
|
2022
Q4 | $12.3M | Sell |
184,570
-8,534
| -4% | -$555K | ﹤0.01% | 2866 |
|
|
2022
Q3 | $10.4M | Sell |
193,104
-44,478
| -19% | -$2.61M | ﹤0.01% | 2940 |
|
|
2022
Q2 | $13.2M | Buy |
237,582
+9,045
| +4% | +$513K | ﹤0.01% | 2756 |
|
|
2022
Q1 | $16M | Buy |
228,537
+103,610
| +83% | +$7.52M | ﹤0.01% | 2362 |
|
|
2021
Q4 | $12M | Sell |
124,927
-28,259
| -18% | -$2.61M | ﹤0.01% | 2739 |
|
|
2021
Q3 | $13.3M | Buy |
153,186
+10,101
| +7% | +$781K | ﹤0.01% | 2566 |
|
|
2021
Q2 | $11.7M | Buy |
143,085
+38,590
| +37% | +$3.21M | ﹤0.01% | 2802 |
|
|
2021
Q1 | $9.94M | Buy |
104,495
+29,997
| +40% | +$2.84M | ﹤0.01% | 2659 |
|
|
2020
Q4 | $4.62M | Sell |
74,498
-87,913
| -54% | -$5.01M | ﹤0.01% | 3340 |
|
|
2020
Q3 | $9.66M | Buy |
162,411
+77,691
| +92% | +$5.3M | ﹤0.01% | 2061 |
|
|
2020
Q2 | $5.91M | Buy |
84,720
+54,513
| +180% | +$3.46M | ﹤0.01% | 2500 |
|
|
2020
Q1 | $1.37M | Sell |
30,207
-162,820
| -84% | -$9.23M | ﹤0.01% | 3693 |
|
|
2019
Q4 | $12.6M | Buy |
193,027
+129,313
| +203% | +$8.64M | ﹤0.01% | 2147 |
|
|
2019
Q3 | $3.96M | Buy |
63,714
+10,736
| +20% | +$674K | ﹤0.01% | 3124 |
|
|
2019
Q2 | $3.77M | Buy |
52,978
+35,691
| +206% | +$2.63M | ﹤0.01% | 3218 |
|
|
2019
Q1 | $1.36M | Sell |
17,287
-183,801
| -91% | -$13.9M | ﹤0.01% | 3896 |
|
|
2018
Q4 | $17M | Buy |
201,088
+7,300
| +4% | +$778K | 0.01% | 1605 |
|
|
2018
Q3 | $33.2M | Sell |
193,788
-18,880
| -9% | -$2.85M | 0.01% | 1247 |
|
|
2018
Q2 | $27.5M | Buy |
212,668
+77,667
| +58% | +$8.67M | 0.01% | 1345 |
|
|
2018
Q1 | $13.9M | Sell |
135,001
-54,179
| -29% | -$5.36M | ﹤0.01% | 2021 |
|
|
2017
Q4 | $16.2M | Buy |
189,180
+29,736
| +19% | +$2.58M | ﹤0.01% | 1899 |
|
|
2017
Q3 | $13.5M | Buy |
159,444
+111,275
| +231% | +$8.81M | ﹤0.01% | 1973 |
|
|
2017
Q2 | $3.65M | Sell |
48,169
-10,116
| -17% | -$708K | ﹤0.01% | 3216 |
|
|
2017
Q1 | $3.85M | Sell |
58,285
-77,686
| -57% | -$5.11M | ﹤0.01% | 3140 |
|
|
2016
Q4 | $8.62M | Buy |
135,971
+74,666
| +122% | +$4.71M | ﹤0.01% | 2419 |
|
|
2016
Q3 | $3.9M | Sell |
61,305
-147,587
| -71% | -$10.8M | ﹤0.01% | 2914 |
|
|
2016
Q2 | $15.5M | Buy |
208,892
+1,717
| +0.8% | +$127K | 0.01% | 1625 |
|
|
2016
Q1 | $13.8M | Buy |
207,175
+70,527
| +52% | +$4.29M | 0.01% | 1607 |
|
|
2015
Q4 | $9.24M | Buy |
136,648
+108,551
| +386% | +$6.7M | ﹤0.01% | 2059 |
|
|
2015
Q3 | $1.5M | Sell |
28,097
-90,254
| -76% | -$5.48M | ﹤0.01% | 3769 |
|
|
2015
Q2 | $7.45M | Buy |
118,351
+105,263
| +804% | +$5.74M | ﹤0.01% | 2404 |
|
|
2015
Q1 | $630K | Sell |
13,088
-5,029
| -28% | -$193K | ﹤0.01% | 4490 |
|
|
2014
Q4 | $601K | Sell |
18,117
-8,068
| -31% | -$262K | ﹤0.01% | 4530 |
|
|
2014
Q3 | $767K | Sell |
26,185
-7,855
| -23% | -$261K | ﹤0.01% | 4267 |
|
|
2014
Q2 | $1.32M | Sell |
34,040
-20,749
| -38% | -$842K | ﹤0.01% | 3822 |
|
|
2014
Q1 | $2.3M | Sell |
54,789
-30,050
| -35% | -$1.25M | ﹤0.01% | 3299 |
|
|
2013
Q4 | $2.78M | Buy |
84,839
+18,949
| +29% | +$617K | ﹤0.01% | 3119 |
|
|
2013
Q3 | $1.78M | Sell |
65,890
-17,068
| -21% | -$480K | ﹤0.01% | 3327 |
|
|
2013
Q2 | $1.94M | Buy |
+82,958
| New | +$1.49M | ﹤0.01% | 3178 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Morgan Stanley's LGND Position: Q1 2026 in Review
Morgan Stanley reduced its Ligand Pharmaceuticals (LGND) stake by 14% in Q1 2026, selling an estimated $5.18M and leaving 167,229 shares worth $33.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2495.
Morgan Stanley first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $36.6M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Morgan Stanley held 167,229 shares of Ligand Pharmaceuticals worth $33.4M as of Q1 2026.
- Morgan Stanley sold 26,173 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.18M.
- Ligand Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2495 holding.
- Morgan Stanley first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Ligand Pharmaceuticals position peaked at $36.6M in Q4 2025.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.